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Abstract
Introduction. Turner syndrome (TS) is the form of gonadal malfunction. Arterial hypertension, elevated LDL and 
glucose and decreased HDL levels are characteristic of TS-women. Hormone therapy is a treatment for short stature 
and sex hormone deficits. Hormonal replacement therapy (HRT) reduces the risk of cardiovascular diseases. A large 
percentage of TS-women do not comply with doctors’ orders regarding HRT. 
The analysis of 17b estradiol(E2) levels and the assessment of blood pressure, lipid and carbohydrate metabolisms in 
TS-women it is possible to state whether HRT decreases the risk of cardiovascular diseases?
Material and methods. The group of 95 TS-women, who declared HRT, were investigated. The information about 
HRT was collected during the anamnesis. E2, total cholesterol (TC), high (HDL) and low (LDL) density lipopro-
teins, triglycerides (TG) and glucose were assessed. Patients were divided into subgroups with E2 ≥ 110 pmol/L  
(n = 34) (HE) and < 110 pmol/L (n = 61) (LE) respectively.
Results. Arterial hypertension was diagnosed in 26.3%. The groups did not differ in systolic 119 ± 20 versus 118 ± 
14 and diastolic 82 ± 13 versus 80 ± 10 mm Hg blood pressure. Despite the higher concentrations of E2 in HE, no 
differences were found in weights, lipids and glucose concentrations. Negative correlations between E2 and body mass 
(r = –0.25, p = 0.04) and diastolic blood pressure (r = –0.28, p = 0.02) as well as positive between E2 and glucose  
(r = 0.24, p < 0.05) were observed only in HE. No correlations between E2 and lipids were found.
Conclusions. 1. Only 1/3 TS-women, who declare HRT, have a satisfactory level of E2.
2. In TS-women HRT does not affect glucose and lipid metabolisms.
3. Negative correlation between E2 and diastolic blood pressure in TS-women suggest beneficial effect of estrogens 
in hypertension.
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Streszczenie
Wstęp. Zespół Turnera (ZT) jest formą uszkodzenia gonad. U kobiet z ZT często występują nadciśnienie tętnicze 
oraz zaburzenia gospodarki węglowodanowej i  lipidowej. Terapia hormonalna w ZT służy leczeniu niskorosłości 
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i  niedoboru hormonów płciowych. Hormonalna terapia zastępcza (HTZ) redukuje ryzyko chorób sercowo-na-
czyniowych. Duży odsetek kobiet z ZT nie stosuje się do zaleceń lekarskich.
Poprzez pomiar stężenia 17b estradiolu (E2), ciśnienia tętniczego oraz ocenę metabolizmu lipidowego i węglow-
odanowego w ZT możemy ocenić, czy HTZ zmniejsza ryzyko chorób układu krążenia?
Materiał i metody. U 95 kobiet z ZT, które podczas anamnezy deklarowały stosowanie HTZ, zmierzono ciśnienie 
tętnicze, oznaczono stężenia E2, cholesterolu całkowitego (TC), lipoprotein wysokiej (HDL) i niskiej (LDL) gęstości, 
triglicerydów (TG) oraz glukozy w surowicy. Badane podzielono na podgrupy, w której E2 ≥ 110 pmol/l n = 34 (HE) 
i < 110 pmol/l n = 61 (LE).
Wyniki. Nadciśnienie tętnicze stwierdzono u  26,3%. Obie grupy nie różniły się wartościami ciśnienia tętniczego 
skurczowego 119 ± 20 v. 118 ± 14 i rozkurczowego 82 ± 13 v. 80 ± 10 mm Hg. Mimo znacznie wyższego stężenia E2, 
w grupie HE nie stwierdzono różnic w masie ciała oraz stężeń lipidów i glukozy. Ujemne korelacje między E2 i masą ciała 
(r = –0,25; p = 0,04) oraz między E2 i ciśnieniem rozkurczowym (r = –0,28; p = 0,02) oraz dodatnią między stężeniami E2 
i glukozy (r = 0,24; p < 0,05) stwierdzono tylko w grupie HE. Nie stwierdzono korelacji między E2 i stężeniami lipidów. 
Wnioski. 1.Tylko 1/3 kobiet z ZT, które deklarują stosowanie HTZ ma zadowalające stężenie estradiolu.
2. Suplementacja estrogenów u kobiet z ZT nie wpływa na stężenie glukozy i lipidów. 
3.Ujemna korelacja między E2 i ciśnieniem rozkurczowym sugeruje korzystny wpływ estrogenów w nadciśnieniu tętniczym. 
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Background
Turner syndrome (TS) is named after Dr. Henry 
Turner, who described the disorder in 1938. TS oc-
curs in women and is characterized by abnormalities 
in the quantity or structure of sex chromosomes. 
The syndrome is most frequently characterized by 
gonadal dysgenesis and somatic disorders, the most 
important of which, is short stature [1, 2]. Hormonal 
studies typically reveal the low circulating concentra-
tions of ovarian steroids and the high concentrations 
of gonadothropins in women aged 14 and over. In 
very few women with TS, the ovaries show cyclic 
hormonal activity manifested by the menstrual cy-
cle and even fertility [3]. TS includes a wide range 
of chromosomal karyotypes and clinical phenotypes 
[4]. The patients exhibit a wide variety of anomalies 
and pathologies within different organs. Neverthe-
less, the clinical features of TS have not been fully 
resolved [5]. Basic phenotypic abnormalities occur in 
the tissues of mesodermal origin. TS is characterized 
by the expression of different phenotypes, and phys-
ical stigmata can be mild or absent [6]. TS affects one 
in every 2500 women. Hence, it can be speculated 
there are approximately 8000 women with Turner 
syndrome in Poland of whom 5000 are over 18 years 
old. Compared to the ‘general’ population, morbid-
ity and mortality are increased. The risk to die from 
Turner syndrome among women is four times higher 
than in the rest of the population [7, 8]. Structural 
heart defects are found in a  quarter to half of the 
women with TS. It mainly involves the left side 
of the heart, including bicuspid aortic valve, aortic 
arch abnormalities and progressive dilation of the as-
cending aorta [9, 10]. Aortic dissection sometimes is 
a fatal complication in Turner syndrome women. The 
risk of arterial hypertension prevalent in TS women. 
It is widely known that higher blood pressure, ele-
vated LDL and glucose as well as decreased HDL 
levels are typical of TS women [11]. Overweight, 
obesity and a  higher percentage of whole-body fat 
mass increased the risk for both types of diabetes 
1 and 2 [12]. Arterial hypertension is reported in 
13–58% of adult Turner syndrome patients and con-
fers an increased risk for cerebrovascular disease and 
aortic dissection, adding significantly to the medical 
burden of Turner syndrome [13]. The cause of hyper-
tension in Turner syndrome is multi-factorial [14]. 
Factors involved in the pathogenesis of hypertension 
and diabetes include inappropriate activation of the 
renin–angiotensin–aldosterone (RAA) system, oxida-
tive stress, inflammation, impaired insulin-mediated 
vasodilatation, increased stimulation of sympathetic 
nervous system (SNS) and abnormal sodium excre-
tion by the kidney [15]. The contribution of both 
RAA axis and SNS in the pathogenesis of hyperten-
sion remains uncertain. SNS is rather over-activated 
in TS women [16]. 
Hormone therapy in TS patients is not only 
a treatment for short stature (growth hormone) and 
the compensation for sex hormone deficit (sex hor-
mones), but also the counteraction to the deficit 
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effects, including the reduction in the risk of car-
diovascular diseases. Oestrogens not only contribute 
to the normal autonomous regulation. They also 
regulate vascular function by modulation cascades 
RAA system and endothelin, by their antioxidant 
activity [17], and reduction of inflammation with 
an increased C-reactive protein, positively influence 
dyslipidaemia with an unfavourable atherogenic pro-
file. Not all the effects of oestrogens are documented 
in TS patients. In our previous study we recognize 
that TS-women, who receive HRT, use this method 
of treatment insufficiently [18]. A large percentage of 
women with TS do not comply with doctors’ orders 
regarding hormonal treatment. Therefore by analys-
ing gonadal hormones concentrations and assessing 
the risk factors of cardiovascular diseases we can ven-
ture to answer the question: whether HRT decreases 
the risk of occurrence of cardiovascular diseases in TS 
women or not?
The aim of this study was to assess the lipid and 
carbohydrate metabolisms as well as blood pressure 
in TS women who declared using HRT in the con-
text of the blood concentration of 17b estradiol (E2).
Material and methods
Investigations were conducted since 1995 year. 
Clinical subjects counted 176 women with Turner 
syndrome at the age ranging from 18 to 53 years, 
mean 24.6 ± 7.7, height 145 ± 7.1 (123–172) cm, 
and weight 50 ± 9.8 (28.8–80) kg, BMI 23.8 ± 4.2 
(14.2–36.2) kg/m2. Blood pressure was measured in 
office. Hypertension was defined as systolic blood 
pressure ≥ 140 and diastolic blood pressure ≥ 90 
mm Hg. Some patients were under antihyperten-
sive treatment. They were also counted as hyperten-
sives. The number of hypetensive TS women was 46 
(26.1%). Only 95 women with TS, who declared 
using hormonal replacement therapy (HRT) (25 ± 
8 years) were included in the study. The information 
about the application of HRT was collected during 
the anamnesis. In all TS women the concentration of 
17b estradiol (E2) was measured. The total cholester-
ol (TC), high and low density lipoprotein (HDL and 
LDL), triglycerides (TG) and glucose blood serum 
concentrations were also assessed. Turner syndrome 
was diagnosed in each of the examined women and 
confirmed by karyotyping [6]. This group of pa-
tients was divided into two subgroups in which E2 ≥ 
110 pmol/L (n = 34) — HE and the second group 
with E2 < 110 pmol/L (n = 61) — LE. The col-
lected research material was statistically computed 
with the use of the program STATISTICA 12 (data 
analysis software system), StatSoft, Inc. Results were 
introduced as a mean value ± standard deviation. To 
compare the given results we used U Mann-Whit-
ney-Test. Correlation analyses were conducted using 
the t Kendall test. Relevance level was assumed as 
a = 0.05. 
Results
Arterial hypertension was diagnosed in 25 TS wom-
en (26.3%). In group HE 8 (23.5%) and LE 17 
(27.9%). Both groups did not differ also in systolic 
119 ± 20 vs 118 ± 14 mm Hg and diastolic 82 ± 13 
vs 80 ± 10 mm Hg blood pressure. The mean values 
of body mass, lipid metabolism and glucose param-
eters in TS patients with low and normal estradiol 
levels are presented in table I. 
In HE group despite the significantly higher con-
centrations of E2, we did not find differences in 
weights, the lipid metabolism parameters and glu-
cose concentrations as compared to LE group. No 
correlations between E2 and analyzed lipid metab-
olism parameters were found in both groups of TS 
women. Negative correlations between E2 and body 
mass (t = –0.25, p = 0.04) as well as between E2 and 
diastolic blood pressure (t = –0.28, p = 0.02) were 
found only in the HE group. This group is also char-
acterized by the positive correlation between the E2 
and glucose levels (r = 0.24, p < 0.05).
Table I. Body mass, 17b estradiol (E2), the total cholesterol (TC), high and low density lipoproteins (HDL and LDL), triglycerides (TG) and 
glucose blood serum concentrations of 95 women with Turner syndrome with low (LE) and normal (HE) estradiol levels, who declared us-
ing HRT. Means ± SD; *p < 0.001
Tabela I. Masa ciała, stężenie 17-b-estradiolu (E2), cholesterolu całkowitego (TC), lipoprotein wysokiej (HDL) i niskiej (LDL) gęstości, trój-
glicerydów (TG) i glukozy w surowicy krwi u 95 kobiet z zespołem Turnera, z niskim (LE) i prawidłowym stężeniem estradiolu, które dekla-
rowały stosowanie HTZ. Wartości średnie ± SD; *p < 0,001














HE (n = 34) 49 ± 8 284 ± 163* 4.9 ± 0.9 1.5 ± 0.4 3.2 ± 0.8 0.9 ± 0.4 5.1 ± 0.7
LE (n = 61) 50 ± 9 53 ± 10 4.9 ± 0.9 1.4 ± 0.4 3.3 ± 0.9 1.1 ± 0.6 5 ± 0.7
Tomasz Jerzy Irzyniec, Wacław Jeż Hypertension in Turner syndrome
209www.ah.viamedica.pl
Discussion
Arterial hypertension is observed in 13–58% TS 
women. The reported prevalence of hypertension 
can partially be attributed to the varying defini-
tions of hypertension [13]. In our study, blood 
pressure was measured in office. In our group of 
women with Turner syndrome, elevated blood 
pressure and hypertension were diagnosed in 25 
TS women (26.3%). Elevated blood pressure adds 
to the increased morbidity and mortality of Turner 
syndrome. Arterial hypertension should be care-
fully diagnosed and rigorously treated. An import-
ant role, as a  cause of high blood pressure, plays 
the activity of the sympathetic nervous system. 
Oestrogen deficiency due to gonadal malfunction 
contributes to the problem, both by stimulating 
sympathetic activity and promoting a  metabolic 
syndrome. The impact of oestrogens on metabo-
lism of lipids is well established. Oestrogens di-
minish lipids oxidation and increase the synthesis 
of triglycerides. Changes in the content of serum 
lipids explain the increase in HDL concentrations 
and the slight decrease in LDL and TC levels. The 
TG concentration and the storage of lipids also 
increase [19]. However, the application of HRT 
does not affect the lipid metabolism in women 
with Turner syndrome [11]. Perhaps the dose of 
HRT in TS women is to low? To this moment 
the optimal dose of HRT and form of applica-
tion in the substitutive treatment of women with 
TS has not been established so far [20]. On the 
other hand a  large percentage of women with TS 
does not comply with doctors’ orders regarding 
hormonal treatment. In our material only half of 
patients (54%) declared using HRT [18]. However, 
only 1/3 TS women who declared using HRT have 
a satisfactory level of estradiol. 
In our study, we did not observe any differences 
in lipid metabolism parameters in women who use 
HRT compared to those who do not. The tim-
ing, duration, and compliance with HRT treatment 
among the HRT-treated subjects were sometimes 
difficult to establish. Nevertheless, our finding that 
HRT-treated TS women with estradiol concentra-
tions either above or below 110 pmol/L had no dif-
ferences in lipid parameters supports the hypothesis 
that HRT does not have a beneficial impact on the 
lipids. However, we cannot exclude that HRT has 
a positive effect on blood pressure. The results of the 
correlation analysis indicate a  positive correlation 
between E2 and glucose concentrations, which is 
well known. The negative correlation between the 
E2 concentration and body mass as well as between 
E2 and diastolic blood pressure in TS women with E2 
concentration ≥ 110 pmol/L indicates a beneficial ef-
fect of estradiol on the above mentioned parameters. 
Conclusions
1. In TS women who declared using HRT only 1/3 
have a satisfactory level of estradiol. 
2. The hormone replacement therapy in women 
with TS does not affect significantly the glucose 
and lipid metabolism. 
3. The negative correlations between E2 and body 
mass and diastolic blood pressure in TS women 
suggests beneficial effect of estrogens in the treat-
ment of arterial hypertension.
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